Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: A comprehensive review

Tropical Medicine and International Health

Volumn 14, Issue 10, 2009, Pages 1287-1302

  Louie, Karly S ^a,b   De Sanjose, Silvia ^b,c   Mayaud, Philippe ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

Cervical cancer; Cervical screening; HIV; HPV vaccine; Human papillomavirus; Sub Saharan Africa

Indexed keywords

VACCINE;

CANCER; DISEASE CONTROL; DISEASE INCIDENCE; EPIDEMIOLOGY; HEALTH STATUS; HUMAN IMMUNODEFICIENCY VIRUS; VACCINE; VIRAL DISEASE; VIRUS; WOMENS HEALTH;

AFRICA; CANCER INCIDENCE; CANCER SCREENING; CARCINOGENESIS; CLINICAL ASSESSMENT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; GENOTYPE; HEALTH CARE SYSTEM; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNIZATION; IMMUNOGENICITY; INFECTION RISK; NONHUMAN; POPULATION RESEARCH; REVIEW; SENEGAL; SEXUAL BEHAVIOR; STANDARDIZATION; TANZANIA; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; WART VIRUS;

ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; AGED; CHILD; FEMALE; HEALTH BEHAVIOR; HIV INFECTIONS; HUMANS; INCIDENCE; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

AFRICA; EAST AFRICA; SENEGAL; SUB-SAHARAN AFRICA; TANZANIA; WEST AFRICA;

HUMAN PAPILLOMAVIRUS;

EID: 70349232537     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2009.02372.x     Document Type: Review

References (63)

1. ACOG Practice Bulletin (2005) Clinical management guidelines for obstetrician-gynecologists. Number 61, April 2005. Human papillomavirus. Obstetrics and Gynecology 105, 905 918.
2. Ahdieh L, Munoz A, Vlahov D, Trimble CL, Timpson LA Shah K (2000) Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and - seronegative women. American Journal of Epidemiology 151, 1148 1157.
3. Ahdieh-Grant L, Li R, Levine AM et al. (2004) Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. Journal of the National Cancer Institute 96, 1070 1076.
4. Batson A, Meheus F Brooke S (2006) Chapter 26: Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries. Vaccine 24 (Suppl 3 S3\219 S3\225.
5. Blossom DB, Beigi RH, Farrell JJ et al. (2007) Human papillomavirus genotypes associated with cervical cytologic abnormalities and HIV infection in Ugandan women. Journal of Medical Virology 79, 758 765.
6. Blumenthal PD, Gaffikin L, Deganus S, Lewis R, Emerson M Adadevoh S (2007) Cervical cancer prevention: safety, acceptability, and feasibility of a single-visit approach in Accra, Ghana. American Journal of Obstetrics Gynecology 196, 407 408.
7. Bosch FX, Lorincz A, Munoz N, Meijer CJ Shah KV (2002) The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology 55, 244 265. (Pubitemid 34293391)
8. Brown A, Jejeebhoy S, Shah I Yount K (2001) Sexual relations among young people in developing countries: evidence from WHO case studies. World Health Organization, Department of Reproductive Health and Research, Geneva.
9. Castellsague X, Bosch FX, Munoz N et al. (2002) Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. The New England Journal of Medicine 346, 1105 1112. (Pubitemid 34984600)
10. Cleland J, Ali MM Shah I (2006) Trends in protective behaviour among single vs. married young women in sub-Saharan Africa: the big picture. Reproductive Health Matters 14, 17 22.
11. Clifford GM, Goncalves MA Franceschi S (2006) Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 20, 2337 2344.
12. Clifford GM, Polesel J, Rickenbach M et al. (2005) Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. Journal of the National Cancer Institute 97, 425 432.
13. Curado M, Edwards B, Shin H et al. (2007) Cancer Incidence in Five Continents, Vol. IX. IARC, Scientific Publications No 160, Lyon.
14. de Sanjose S, Tous S, on behalf of RIS HPV TT Study Group (2009) Worldwide HPV genotype distribution in 10,365 cases of cervical cancer. Programs and Abstracts of the 25th International Papillomavirus Conference and Clinical Workshop; May 8-14 2009; Malmo, Sweden Abstract P30.13.
15. De Vuyst H, Gichangi P, Estambale B, Njuguna E, Franceschi S Temmerman M (2008) Human papillomavirus types in women with invasive cervical carcinoma by HIV status in Kenya. International Journal of Cancer 122, 244 246.
16. Denny L, Kuhn L, Pollack A Wright TC (2002) Direct visual inspection for cervical cancer screening: an analysis of factors influencing test performance. Cancer 94, 1699 1707.
17. Denny L, Quinn M Sankaranarayanan R (2006) Chapter 8: Screening for cervical cancer in developing countries. Vaccine 24 (Suppl 3 S71 S77.
18. Didelot-Rousseau MN, Nagot N, Costes-Martineau V et al. (2006) Human papillomavirus genotype distribution and cervical squamous intraepithelial lesions among high-risk women with and without HIV-1 infection in Burkina Faso. British Journal of Cancer 95, 355 362.
19. Dillner J, Rebolj M, Birembaut P et al. (2008) Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337, a1754.
20. Ferlay J, Bray F, Pisani P Parkin DM (2004) GLOBOCAN 2002 cancer incidence. Mortality and prevalence worldwide. IARC CancerBase No 5 version 2 0, IARC Press, Lyon.
21. Garland S, Brotherton J, Skinner R et al. (2008) Human papillomavirus and cervical cancer in Australasia and Oceania: risk factors, epidemiology and prevention. Vaccine 26S, M80 M88.
22. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD et al. (2005) Cost-effectiveness of cervical-cancer screening in five developing countries. The New England Journal of Medicine 353, 2158 2168.
23. Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S Kim SY (2008) Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 26, 4080 4093.
24. Gravitt P, Coutlee F, Iftner T, Sellors J, Quint W Wheeler C (2008) New technologies in cervical cancer screening. Vaccine 26, K42 K52.
25. Hawes SE, Critchlow CW, Sow PS et al. (2006) Incident high-grade squamous intraepithelial lesions in Senegalese women with and without human immunodeficiency virus type 1 (HIV-1) and HIV-2. Journal of the National Cancer Institute 98, 100 109.
26. Heard I, Schmitz V, Costagliola D, Orth G Kazatchkine MD (1998) Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS 12, 1459 1464.
27. Hessol NA, Seaberg EC, Preston-Martin S et al. (2004) Cancer risk among participants in the women's interagency HIV study. Journal of Acquired Immune Deficiency Syndromes 36, 978 985.
28. HPV Information Centre (2009) Human papillomavirus and related cancers 2009. WHO\ICO Information Centre on HPV and Cervical Cancer (http://www.whoint/ hpvcentre).
29. IARC Screening Group (2009) Cervical Cancer Screening Activities Directory (CxCaScreen): Research Projects\Programmes (http://screening.iarc.fr/ activ/activity.php?lang=1). IARC Screening Group. 2009. Accessed 1 July 2009.
30. Jamieson DJ, Duerr A, Burk R et al. (2002) Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. American Journal of Obstetrics Gynecology 186, 21 27.
31. Kane MA, Sherris J, Coursaget P, Aguado T Cutts F (2006) Chapter 15: HPV vaccine use in the developing world. Vaccine 24 (Suppl 3 S3\132 S3\139.
32. Kawonga M Fonn S (2008) Achieving effective cervical screening coverage in South Africa through human resources and health systems development. Reproductive Health Matters 16, 32 40.
33. Khan MJ, Castle PE, Lorincz AT et al. (2005) The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. Journal of the National Cancer Institute 97, 1072 1079.
34. Kitchener H, Nelson L, Adams J et al. (2007) Colposcopy is not necessary to assess the risk to the cervix in HIV-positive women: an international cohort study of cervical pathology in HIV-1 positive women. International Journal of Cancer 121, 2484 2491.
35. Kuhn L, Denny L, DeSousa M Wright TC (2009) Screen-and-treat using HPV testing is highly effective among HIV-infected women. Programs and Abstracts of the 25th International Papillomavirus Conference and Clinical Workshop; May 8-14, 2009; Malmo, Sweden (Abstract O-16.01).
36. Lehtinen M, Herrero R, Mayaud P et al. (2006) Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine 24 (Suppl 3 S3\233 S3\241.
37. Levin C, Sellors J, Ortendahl J et al. (2008) Cost-Effectiveness of Cerivcal Cancer Prevention in China. 24th International Papillomavirus Conference and Clinical Workshop Beijing, China, November 3-9 2007 Abstracts Book [Abstract 6B-07].
38. Lillo FB, Ferrari D, Veglia F et al. (2001) Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. The Journal of Infectious Diseases 184, 547 551.
39. Louie KS, de Sanjose S, Diaz M et al. (2009) Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. British Journal of Cancer 100, 1191 1197.
40. Mayaud P, Gill DK, Weiss HA et al. (2001) The interrelation of HIV, cervical human papillomavirus, and neoplasia among antenatal clinic attenders in Tanzania. Sexually Transmitted Infections 77, 248 254.
41. Moore AL, Sabin CA, Madge S, Mocroft A, Reid W Johnson MA (2002) Highly active antiretroviral therapy and cervical intraepithelial neoplasia. AIDS 16, 927 929.
42. Moscicki AB, Schiffman M, Kjaer S Villa LL (2006) Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine 24 (Suppl 3 S42 S51.
43. Moscicki AB, Weinberg A, Song LY et al. (2009) Safety and Immunogenicity of Gardasil in HIV-infected Children. Programs and Abstracts of the 25th International Papillomavirus Conference and Clinical Workshop; May 8-14 2009; Malmo, Sweden (Abstract O-16.02).
44. Muwonge R, Mbalawa CG, Keita N et al. for the IARC Multicentre Study Group on Cervical Cancer Early Detection (2009) Performance of colposcopy in five sub-Saharan African countries. British Journal of Obstetrics & Gynaecology 116, 829 837.
45. Orlando G, Fasolo MM, Schiavini M, Signori R Cargnel A (1999) Role of highly active antiretroviral therapy in human papillomavirus-induced genital dysplasia in HIV-1-infected patients. AIDS 13, 424 425. (Pubitemid 29095109)
46. Palefsky JM, Gillison ML Strickler HD (2006) Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 24 (Suppl 3 S140 S146.
47. Parkin DM Bray F (2006) Chapter 2: The burden of HPV-related cancers. Vaccine 24 (Suppl 3 S3\11 S3\25.
48. Parkin DM, Sitas F, Chirenje M, Stein L, Abratt R Wabinga H (2008) Part I: Cancer in Indigenous Africans - burden, distribution, and trends. Lancet Oncology 9, 683 692.
49. PATH (2009) Cervical Cancer Prevention initiatives at PATH. http://www rho org/files/PATH-cxca-rep-to-world pdf Accessed: 20 January 2009.
50. Qiao YL, Sellors JW, Eder PS et al. (2008) A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. The Lancet Oncology 9, 929 936.
51. Sahasrabuddhe VV, Mwanahamuntu MH, Vermund SH et al. (2007) Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia. British Journal of Cancer 96, 1480 1483.
52. Sankaranarayanan R, Bhatla N, Gravitt P et al. (2008) Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka, and Nepal. Vaccine 26S, M43 M52.
53. Sankaranarayanan R, Budukh AM Rajkumar R (2001) Effective screening programmes for cervical cancer in low-and middle-income developing countries. Bulletin of the World Health Organization 79, 954 962.
54. Sankaranarayanan R, Esmy PO Rajkumar R (2007) Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 370, 398 406.
55. Sankaranarayanan R, Nene BM, Shastri SS et al. (2009) HPV screening for cervical cancer in rural India. The New England Journal of Medicine 360, 1385 1394.
56. Schiffman M, Herrero R Desalle R (2005) The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337, 76 84.
57. Schiller J, Castellsague X, Villa L Hildesheim A (2008) An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26 (Suppl. 10 K53 K61.
58. Schuman P, Ohmit SE, Klein RS et al. (2003) Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. The Journal of Infectious Diseases 188, 128 136. (Pubitemid 36829752)
59. Strickler HD, Palefsky JM Burk RD (2008) HPV types present in invasive cervical cancers of HIV-seropositive women. International Journal of Cancer 123, 1224 1225.
60. Strickler HD, Palefsky JM, Shah KV et al. (2003) Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. Journal of the National Cancer Institute 95, 1062 1071.
61. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ Wright TC (1997) Human papillomavirus infection in women infected with the human immunodeficiency virus. The New England Journal of Medicine 337, 1343 1349.
62. UNAIDS (2008) Report on the Global AIDS Epidemic, December 2008. UNAIDS, Geneva.
63. WHO (2002) World Health Survey 2001\2002. World Health Organization, Geneva.